Compare LCUT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | LITS |
|---|---|---|
| Founded | 1945 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 55.9M |
| IPO Year | 1991 | N/A |
| Metric | LCUT | LITS |
|---|---|---|
| Price | $3.89 | $1.38 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 63.1K | ★ 501.7K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,066,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $1.46 |
| 52 Week High | $6.82 | $9.00 |
| Indicator | LCUT | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | N/A |
| Support Level | $3.82 | N/A |
| Resistance Level | $4.11 | N/A |
| Average True Range (ATR) | 0.27 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 23.33 | 0.00 |
Lifetime Brands Inc is a U.S. based company that designs, sources, and sells branded kitchenware, tableware, and other products used in the home and markets its products under brands such as Farberware, KitchenAid, Mikasa, and others. The company markets and sells its products principally on a wholesale basis to retailers. It also markets and sells a limited selection of its products directly to consumers through its Pfaltzgraff, Mikasa, Fred, and Friends, Built NY, and others. Its products include kitchen tools, gadgets, cutlery, dinnerware, and glassware. The segments of the company are the U.S. and International. It derives a majority of its revenue from the U.S. segment. The company derives maximum revenue from Kitchenware products.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.